Illumina Investor Presentation — January 2022

Document content

© 2022 Illumina, Inc. All rights reserved.

President & CEO, IlluminaFrancis deSouza40thAnnual

J.P. Morgan Healthcare ConferenceJ.P. MORGAN HEALTHCARE CONFERENCE JANUARY 10, 2022Cautionary Notes on Forward Looking Statements2 J.P. MORGAN HEALTHCARE CONFERENCE

This release may contain forward- looking statements that involve risks and uncertainties. Among the important

factors to which our business is subject that could cause actual results to differ materially from those in any forward-

looking statements are: ( i) the impact to our business and operating results of the COVID -19 pandemic; (ii)

challenges inherent in developing, manufacturing, and launching new products and services, (iii) our ability to further

develop and commercialize our instruments, consumables, and products, including Galleri , the cancer screening test

developed by GRAIL; (iv) the risks and costs associated with the integration of, and our ability to integrate, GRAIL’s

business successfully to achieve anticipated synergies, including the restrictions on integration while we are subject

to the European Commission’s order to keep GRAIL separate from us; (v) the risk that disruptions from the

consummation of our recent acquisition of GRAIL or any associated legal or regulatory proceedings or obligations

will harm our business, including current plans and operations; (vi) potential adverse reactions or changes to

business relationships resulting from the consummation of our recent acquisition of GRAIL; (vii) our ability to

successfully partner with other companies and organizations to develop new products, expand markets, and grow

our business, together with other factors detailed in our filings with the Securities and Exchange Commission,

including our most recent filings on Forms 10- K and 10- Q, or in information disclosed in public conference calls, the

date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these

forward- looking statements, to review or confirm analysts’ expectations, or to provide interim reports or updates on

the progress of the current quarter.Improve human health by unlocking the power of the genomeOUR MISSIONIllumina Sequencing Technology is Leading the

Rapidly Growing Genomics Diagnostic Tools MarketJ.P. MORGAN HEALTHCARE CONFERENCE

2021 revenue*Mid-Teens %

revenue growth target>400K

PublicationsWe enable clinicians and researchers to comprehensively

understand and leverage the genome4

For Research Use Only. Not for use in diagnostic procedures.Strong Finish to 2021 with 25% Revenue Growth in Q4J.P. MORGAN HEALTHCARE CONFERENCE